The International Conference on Harmonisation E14 (2004) calls for public comment by statisticians on the practical implications of the proposed guidance to monitor for QTc prolongation. Of particular interest is consideration of the statistical properties of various end points proposed for measurement. Methods of analysis and statistical inference are developed for the QTc end points considered.
FitzgeraldG. Coxibs and cardiovascular disease. N Engl J Med.2004;351:1709–1711.
2.
TopolE. Failing the public health—refocoxib, Merck, and the FDA. N Engl J Med.2004;351: 1707–1709.
3.
International Conference on Harmonisation Draft Consensus Guideline, Step 1.The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrythmic Potential for Non-Antiarrythmic Drugs.2005. Available at: http://www.fda.gov/cder/guidance.
4.
JonesBKenwardMG. Design and Analysis of Cross-over Trials, 2nd ed.London: Chapman and Hall, CRC Press; 2003.
5.
Statistical Analysis Software, SAS/STAT User's Guide, Version 8. Cary, NC: SAS Institute; 1999.
6.
PattersonSJonesB. Bioequivalence and Statistics in Clinical Pharmacology.London: Chapman and Hall, CRC Press; 2005.
7.
TempleR. Overview of the concept paper, history of the QT/TdP concern; regulatory implications of QT prolongation. Presentations at Drug Information Agency/FDA Workshop. Available at: www.diahome.org.
8.
HauschkeDHothornL. Safety assessment in toxicological studies: proof of safety versus proof of hazard. In: ChowSLiuJ, eds. Design and Analysis of Animal Studies in Pharmaceutical Development.New York: Marcel Dekker; 1998:197–226.
9.
WellekS. Testing Statistical Hypotheses of Equivalence.London: Chapman and Hall, CRC Press; 2003.
10.
PattersonSAginMAnzianoRInvestigating drug induced QT and QTc prolongation in the clinic: statistical design and analysis considerations. Drug Inf J.2005;39:243–266.
11.
International Conference on Harmonisation.Statistical Principles for Clinical Trials. 1998. Available at: http://www.fda.gov/cder/guidance/.
12.
PattersonS. ICH E14 draft consensus guideline on clinical evaluation of QTc interval prolongation. Pharm Stat.2004;3:289–293.
13.
KenwardMRogerJ. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics.1997;33:983–997.
